Last updated on November 2019

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors


Brief description of study

The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody CLinical Assessment In Man CX-2009 clinical trial 001

PROBODY is a trademark of CytomX Therapeutics, Inc

Clinical Study Identifier: NCT03149549

Find a site near you

Start Over

University of Chicago

Chicago, IL United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

Huntsman Cancer Institute

Salt Lake City, UT United States
  Connect »

Northern Centre for Cancer Care

Newcastle Upon Tyne, United Kingdom
  Connect »